PMI
Philip Morris International Inc. (PMI) (NYSE:PM) today launched “Our World Is Not an Ashtray,” a new global initiative to raise awareness and drive a long-term change in behavior and attitudes around cigarette butt littering. The initiative supports PMI’s litter reduction target—described in its Integrated Report 2019 —to achieve a 50 percent reduction of the plastic litter from its products by 2025 (vs. 2021 baseline). The initiative, launched on WorldNoAshtray.com , aims to educate the public about the environmental impact of cigarette butt littering and inspire adult smokers to change littering habits.
“We seek to make cigarette butt littering socially unacceptable,” said Huub Savelkouls, Chief Sustainability Officer at PMI. “‘Our World Is Not an Ashtray’ is an important initiative in our multipronged approach to addressing this important issue.”
To track progress against its goal, PMI is working with three organizations—Litterati , Cortexia , and CARTO —to implement a data-driven approach and assess the prevalence of cigarette butt litter across the globe; identify litter hotspots; and, monitor the impact of anti-littering activities. A pilot assessment will take place this summer in a pilot city before being rolled out in representative countries across the world in 2021 as part of a five year assessment.
Waste littering is a major environmental concern and was identified as an issue of growing importance for PMI following external assessments, and raised to priority status in its Sustainability Materiality Report at the end of 2019. In a new international study conducted by global research data and insights company Kantar this spring on behalf of PMI, 25 percent of adult smokers reported that they throw cigarette butts on the ground because they “think it is a normal way to dispose of a cigarette.”
The survey also revealed that 75 percent of respondents thought that cigarette filters are made of cotton or paper, and only 13 percent knew that filters are made of plastic. These findings highlight the need for awareness campaigns such as “Our World Is Not an Ashtray” to help change smokers’ behaviors.
Jeff Kirschner, Founder and CEO of Litterati, said: “There’s a widespread view that there’s nothing wrong with stubbing out cigarettes on streets or beaches, yet very few people realize that plastic is the main component in cigarette butts. Litterati began with just one person picking up a cigarette butt, and it has transformed into a global movement that’s empowering people to crowdsource-clean the planet. Together with PMI, we will use our technology to gather behavioral insight on cigarette butt littering, map problem areas, and mitigate future risk. We’re proud to be part of ‘Our World Is Not an Ashtray’ to help address cigarette butt litter worldwide.”
PMI is increasing the scale and reach of its participation in clean-up activities, to raise awareness of the issues of littering—and cigarette butt littering particularly—in local communities. Working with Litterati, PMI will encourage volunteers in every corner of the world to use the organization’s app to geotag litter and join cleanup challenges ranging from local neighborhoods to global initiatives. PMI’s affiliates will also work with local anti-littering organizations, following the participation of over 3,900 PMI volunteers from 31 countries in litter collections on World Cleanup Day 2019 where they collected 83 tons of litter.
Jens Rupp, PMI’s Head of Environmental Sustainability, said: “Cigarette butt litter is a problem that we need to solve; too many cigarette butts are littered, ending up in the natural environment. By working with experts to better understand how to nudge smokers to more responsible disposal habits, launching general population education programs, and cooperating with governments and local authorities to ensure there is an adequate waste disposal infrastructure, we can reduce the plastic litter associated with our products.”
For more on the “Our World Is Not an Ashtray” initiative, visit www.worldnoashtray.com .
For additional information about PMI’s efforts to reduce waste littering and the CBL study, visit www.pmi.com/littering .
Survey Methodology
The global survey was conducted by Kantar, between the third week of March and the first week of May 2020; 12,800 people across 10 countries were questioned, with a 54 percent completion rate. The completion rate reflects the respondents who finished the survey, matched the eligible criteria, provided quality data, and filled quotas considered nationally representative by Kantar (gender and age).
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. For more information, please visit www.pmi.com
and www.pmiscience.com.
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005657/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
